Caris Life Sciences, Inc. (CAI)

NMS – Real vaqt narxi. Valyuta: USD

18.50

-0.20 (-1.07%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

18.72

+0.22 (1.20%)

Bozordan keyin: Jun 26, 2026, 7:43 PM EDT

16.06.2026

Caris Life Sciences Announces Dual Listing on NYSE Texas

IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the dual listing of its common stock on NYSE Texas effective on June 17, 2026, further expanding its presence in the public markets. Caris' shares will continue to be listed and trade on its primary exchange, the NASDAQ, with a dual listing on the NYSE Texas under the same CAI ticker symbol, expected to provide additional exposure to investors, particularly within Texas and the broader U.S. market.

12.06.2026

Caris Life Sciences: The Discount To Peers Looks Hard To Ignore

Caris Life Sciences is rated a buy, combining 79% Q1 2026 revenue growth, 65%+ gross margins, and positive free cash flow. CAI's genomic database of over one million cases underpins future products like Caris Detect, offering a potential competitive edge. At 5x EV/Sales, CAI trades at a discount to peers despite superior growth and profitability, further supported by a $100M buyback.

08.06.2026

Caris Life Sciences, Inc. (CAI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

08.06.2026

Caris Life Sciences Announces Share Repurchase Program

IRVING, Texas, June 8, 2026 /PRNewswire/ -- Caris Life Sciences® (Nasdaq: CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio company and precision medicine pioneer, today announced that its Board of Directors has authorized a share repurchase program for up to $100 million of the Company's outstanding common stock. Under the repurchase program, the Company may repurchase shares from time to time through open market purchases, in privately negotiated transactions, or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

26.05.2026

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

Inaugural story spotlights a woman whose presumed stage 4 metastatic breast cancer diagnosis was corrected by Caris GPSai, an AI-powered tissue-of-origin model, revealing a highly treatable lymphoma IRVING, Texas, May 26, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today launched "Behind the Diagnosis," a new campaign that spotlights patients whose care has been targeted and personalized by Caris' comprehensive molecular profiling and AI-powered precision medicine. The inaugural story features Erika Rios, who was diagnosed prior to Caris testing, with stage 4 metastatic triple-negative breast cancer.

15.05.2026

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types IRVING, Texas, May 15, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the publication of a Caris‑led study in The Oncologist demonstrating the ability of the Caris Lookback Program to proactively identify previously-profiled patients who become eligible for newly approved targeted therapies. Molecular profiling reports from most labs are static, reflecting clinical knowledge only at the time of testing.

13.05.2026

Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%

Caris Life Sciences NASDAQ: CAI executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following its IPO last June.

Videolar

No Data

There is no data to display

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

15.05.2026

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

Caris Life Sciences, Inc. (CAI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Caris Life Sciences, Inc. (CAI)

Caris Life Sciences Announces Dual Listing on NYSE Texas

Caris Life Sciences: The Discount To Peers Looks Hard To Ignore

Caris Life Sciences, Inc. (CAI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Caris Life Sciences Announces Share Repurchase Program

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%

Videolar

No Data

Press-relizlar

Caris Life Sciences Announces Dual Listing on NYSE Texas

Caris Life Sciences Announces Share Repurchase Program

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

Caris Life Sciences Announces Dual Listing on NYSE Texas

Caris Life Sciences: The Discount To Peers Looks Hard To Ignore

Caris Life Sciences, Inc. (CAI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Caris Life Sciences Announces Share Repurchase Program

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%

Videolar

No Data

Press-relizlar

Caris Life Sciences Announces Dual Listing on NYSE Texas

Caris Life Sciences Announces Share Repurchase Program

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

Search stocks

Caris Life Sciences, Inc. (CAI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Caris Life Sciences, Inc. (CAI)

Caris Life Sciences Announces Dual Listing on NYSE Texas

Caris Life Sciences: The Discount To Peers Looks Hard To Ignore

Caris Life Sciences, Inc. (CAI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Caris Life Sciences Announces Share Repurchase Program

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%

Videolar

No Data

Press-relizlar

Caris Life Sciences Announces Dual Listing on NYSE Texas

Caris Life Sciences Announces Share Repurchase Program

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

Caris Life Sciences Announces Dual Listing on NYSE Texas

Caris Life Sciences: The Discount To Peers Looks Hard To Ignore

Caris Life Sciences, Inc. (CAI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Caris Life Sciences Announces Share Repurchase Program

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%

Videolar

No Data

Press-relizlar

Caris Life Sciences Announces Dual Listing on NYSE Texas

Caris Life Sciences Announces Share Repurchase Program

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek